Edition:
United States

Iovance Biotherapeutics Inc (IOVA.OQ)

IOVA.OQ on NASDAQ Stock Exchange Global Market

7.95USD
17 Nov 2017
Change (% chg)

$0.05 (+0.63%)
Prev Close
$7.90
Open
$7.80
Day's High
$8.00
Day's Low
$7.70
Volume
72,560
Avg. Vol
101,911
52-wk High
$8.60
52-wk Low
$4.45

Chart for

About

Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program... (more)

Overall

Beta: 4.57
Market Cap(Mil.): $577.43
Shares Outstanding(Mil.): 72.63
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 197.02 15.79
EPS (TTM): -- -- --
ROI: -- -10.12 12.01
ROE: -- -37.71 15.91

BRIEF-Iovance Biotherapeutics reports Q3 GAAP loss per share $0.35

* Iovance Biotherapeutics Inc reports third quarter 2017 financial results

Oct 31 2017

BRIEF-Iovance Biotherapeutics announces pricing of its public offering of $50 mln of common stock

* Iovance Biotherapeutics, Inc. announces pricing of its public offering of $50 million of common stock

Sep 20 2017

BRIEF-Iovance BioTherapeutics plans to offer $50 mln of common stock​

* Intends to use proceeds from this offering to fund its ongoing clinical trials for its current candidates​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Sep 19 2017

BRIEF-Iovance Biotherapeutics announces approval of 1st clinical trial of LN-145 for treating cervical cancer

* Iovance Biotherapeutics announces approval of first clinical trial application by competent authority in Netherlands for a phase 2 trial of LN-145 for the treatment of patients with cervical cancer Source text for Eikon: Further company coverage:

Sep 13 2017

BRIEF-Iovance Biotherapeutics enters into a research collaboration with the Ohio State University Comprehensive Cancer Center

* Iovance Biotherapeutics enters into a research collaboration focused on hematologic malignancies with the Ohio State University Comprehensive Cancer Center

Sep 07 2017

BRIEF-Iovance Biotherapeutics announces FDA fast track designation for LN-144 for treatment of advanced melanoma

* Iovance Biotherapeutics announces FDA fast track designation for LN-144 for treatment of advanced melanoma Source text for Eikon: Further company coverage:

Aug 31 2017

BRIEF-Iovance Biotherapeutics appoints Timothy Morris as chief financial officer

* Iovance Biotherapeutics appoints Timothy Morris as Chief Financial Officer

Aug 08 2017

BRIEF-Iovance Biotherapeutics loss $0.32/shr

* Iovance Biotherapeutics reports second quarter 2017 financial results

Aug 01 2017

BRIEF-Iovance Biotherapeutics Inc - appointed Franco Valle as interim principal financial officer of company

* Iovance Biotherapeutics Inc - on July 26 company appointed Franco Valle to serve as interim principal financial officer of company Source text: (http://bit.ly/2u3g3QI) Further company coverage:

Jul 27 2017

Earnings vs. Estimates